SCHEMBL513474

SCHEMBL513474

CCC(CC)(c1nc(C)no1)P(=O)(O)O

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 2/20 0.35
CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL512734 0.79 GPR119 (0.31)
SCHEMBL11034475 0.76 PTPRB (0.34) PTPRB
SCHEMBL514330 0.70 NPC1 (0.46)
SCHEMBL513297 0.70
SCHEMBL15116412 0.68 LMNA (0.33) PTPRB
SCHEMBL9863815 0.68 MAPT (0.37)
SCHEMBL6820625 0.68 POLB (0.41) CNR2
SCHEMBL11034468 0.67 KDM1A (0.34)
SCHEMBL11764105 0.66 FDPS (0.39)
SCHEMBL11763139 0.65 FDPS (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 PTPRB 4303/4885CNR2 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.